Suzhou China, February 14, 2024 – TenNor Therapeutics and the First Hospital of Jilin University jointly published a research article in The Lancet Infectious Diseases (Lancet ID), reporting the phase I/II clinical trial results of rifasutenizol (TNP-2198) for the treatment of Helicobacter pylori (H. pylori) infection. The journal also published a commentary on the research by leading experts in the field.

Rifasutenizol is a new molecular entity specifically designed for the treatment of H. pylori infection. It possesses a synergistic dual mechanism of action with a low propensity for the development of antimicrobial resistance. Rifasutenizol exhibited potent activity against H. pylori clinical isolates collected from different regions in China and the United States, including those resistant to antibiotics currently used for the treatment of H. pylori infection. TenNor has completed a series of phase I/II clinical trials in China on rifasutenizol and received an IND, Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. The article published in Lancet ID reported the phase I/II clinical study results, including data from single ascending dose and food effects, multiple ascending dose, dose ranging and regimen development studies.

Lancet ID publishes original research that advocates change in or illuminates infectious disease clinical practice and informative reviews on any topic connected with infectious diseases and human health. The journal’s preference is to publish articles likely to influence clinical practice or thinking. The impact factor of the journal is 56.3, ranking first among 96 infectious disease journals in the world.

Link to the article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00003-3/abstract

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late-stage of clinical development targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com